CRC Research Update — November 02, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Monday, November 02, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TREATMENT
Liposomal irinotecan, capecitabine, and bevacizumab show 8.1-month progression-free survival as second-line therapyIn a multicenter study that enrolled 63 patients with metastatic colorectal cancer who had progressed on oxaliplatin-based first-line therapy, the combination achieved a 22.9% response rate and 89.6% disease control rate among the 48 patients who received at least one tumor assessment, with median overall survival of 19.5 months. (Cancer)
-
RESEARCH
Early-onset colorectal cancer displays distinct immunosuppressive microenvironment and FAT3 mutation biomarkerMultiomics analysis of 69 early-onset and 461 late-onset CRC patients identified 10 genes enriched in early-onset disease, an immunosuppressive microenvironment with elevated regulatory T cells, and FAT3 mutations as a genomic correlate of immune-activated phenotype. (Hum Mutat)
-
LIVING WITH CRC
Meta-analysis identifies optimal exercise dose for improving fitness and quality of lifeAnalysis of 26 randomized trials involving 1,731 patients found that moderate-to-high intensity exercise significantly improved cardiorespiratory fitness and muscular fitness, with prehabilitation interventions showing the strongest effects. (Eur J Sport Sci)
-
SCREENING
Adenoma detection rate of 22% reported in symptomatic patients aged 50 and olderSingle-center analysis of 235 consecutive symptomatic patients undergoing diagnostic colonoscopy found an age-related rise in adenoma prevalence, with those aged 60 and older showing the highest detection rate at 25.4%. (Ceylon Med J)
This week's research spans treatment combinations, genomic profiling, and supportive care across the colorectal cancer continuum.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data